FDA commissioner's contingency fund draws Rep. Barton's attention in Aug. 21 letter to Kessler.
FDA COMMISSIONER "CONTINGENCY FUND" DRAWS REP. BARTON INQUIRY in an Aug. 21 letter to Commissioner Kessler. Barton's (R-Tex.) House Commerce/Oversight & Investigations Subcommittee has "received information that you as [FDA] commissioner have a contingency fund under which you have reportedly used funds at your discretion to fund activities not heretofore disclosed to the Congress," the letter states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth